There was no change even after they adjusted, if possible, to take into account socio-economic status and co – exisiting illnesses. MS to delay conclusions about the use of interferon beta progress Shirani and colleagues conclude:.

But they explain , there are not enough studies to follow the effects of interferon beta to patients in the long run.

The follow-up period differed between the groups. It was much more for the historical untreated group . The median follow-up time for contemporary groups was 5.1 years for treated patients with MS and 4.0 years for the untreated MS patients.Yearsn the world. – Receives Positive ruling, Pat Key Osteoporosis Drug patents in Japan imparting.

‘We believe that that protection of intellectual property can be combined by the patent in Japan, our American and European funding, establishes it of the maximize the value of NB S101 in the major pharmaceutical markets worldwide all over the world ‘said Philip J. President and Chief Executive Officer of of Osteologix.